Eupraxia Pharmaceuticals Inc.

NASDAQ:EPRX

Biotechnology

Healthcare
$6.21 +1.11%

+$0.07 today

Market cap
$417.57M
Beta
1.48
P/E (TTM)
-8.5
EPS (TTM)
-$0.74
52W Low $4.19High $9.32

Volume 1.21M

Average 0.22M

EPRX Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Eupraxia Pharmaceuticals Inc.NASDAQ: EPRX

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow growth accelerates

Q1 FY2026 financing cash flow of $67.63M rose 15631.4% year over year, ahead of the +380.3% change in trailing-twelve-month financing cash flow. Sequentially, it rose 4492.2% from the prior quarter. Over 3 fiscal years it compounded at +92.7% a year.

Context

  • Financing cash flow increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +15631.4% holds above the trailing-twelve-month pace of +380.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$67.63M+4492.2% QoQ
Last fiscal yearDec 2025
$77.33M+68.9% YoY
LTMMar 2026
$122.33M+380.3% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+15631.4%——
1 year+68.9%——
3-year CAGR+92.7%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

Mixed currencies · from the cash flow

Latest · FY2025
77.33M USD
Year-over-year change
+68.9%

Financing Cash Flow vs competitors

How EPRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +380.3% is the highest of 9, against a peer median of +48.2%.
  • Over three fiscal years its annual growth of +92.7% compares with a peer median of +24.0%.
EPRX Competitors
Financing Cash Flow for EPRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€232M EUR+59.4%+84.0%5175.1%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$122.33M USD+380.3%+92.7%—
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$117.69M USD+118.3%+53.0%—
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$94.16M USD+226.3%-5.1%287.7%
TARAProtara Therapeutics, Inc.LTM Mar 2026$82.13M USD-42.0%——
MDWDMediWound Ltd.LTM Mar 2026$30.48M USD+54.5%-6.1%210.5%
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026$16.91M USD———
RNACCartesian Therapeutics, Inc.LTM Mar 2026$15.64M USD-86.7%—881.2%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$1.3M USD+41.9%-27.5%—
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$378K USD-99.8%+634.8%—
Peer median (excluding EPRX) —+48.2%+24.0%584.5%

Competitors are the stored peer set for EPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CAD
FY2022
Dec 2022 · CAD
FY2023
Dec 2023 · USD
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Net Income(18.18M)(18.99M)(21.81M)(25.74M)(39.22M)
Depreciation & Amortization88.17K147.89K117.1K171.72K241.68K
Deferred Income Tax00000
Stock-Based Compensation01.43M1.06M3.22M0
Change in Working Capital(167.16K)1.51M4.03M(6.76M)(725.6K)
Accounts Receivables150.92K230.48K(78.09K)(101.39K)(438.64K)
Inventory00000
Accounts Payables01.32M435.12K(714.88K)2.4M
Other Working Capital(318.07K)(39.96K)3.67M(5.95M)(2.69M)
Other Non-Cash Items6.68M1.5M977.18K(880.5K)10.68M
Operating Cash Flow(11.58M)(14.4M)(15.62M)(29.99M)(29.03M)
Capital Expenditures(341.28K)(235.55K)(55.25K)(104.23K)(598.77K)
Acquisitions (Net)00000
Purchases of Investments(7.12M)(3.27M)000
Sales of Investments013.34M000
Other Investing Activities(3.97M)242029.07K0
Investing Cash Flow(11.42M)9.83M(55.25K)(75.16K)(598.77K)
Debt Repayment9.62M(142.27K)(59.81K)(9.14M)0
Common Stock Issued29.91M10.64M11.96M54.56M77.33M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(69.33K)306.77K3.97M363.06K0
Financing Cash Flow39.46M10.8M15.87M45.78M77.33M
Effect of Forex Changes(63.69K)(507.4K)618.45K(1.96M)(403.1K)
Net Change in Cash16.4M5.73M811.93K13.76M47.3M
Free Cash Flow(11.92M)(14.63M)(15.68M)(30.1M)(29.63M)

Eupraxia Pharmaceuticals Inc.

NASDAQ:EPRX

Intrinsic Alpha fair value

Locked

Current Price

$6.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.